AC
ACET icon

Annandale Capital’s Adicet Bio ACET Stock Holding History

Annandale Capital’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-288
Closed -$65K – 137
2022
Q3 		$65K Buy
+288
New +$73.1K 0.02% 127

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Annandale Capital's ACET Position: Q4 2022 in Review

Annandale Capital sold out of Adicet Bio (ACET) in Q4 2022, closing a stake of 288 shares — an estimated $65K sold.

Annandale Capital first reported a position in ACET in Q3 2022 and held it in 1 quarter. The position peaked at $65K in Q3 2022. 100 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

  • Annandale Capital reported no remaining Adicet Bio position as of Q4 2022 after selling out during the quarter.
  • Annandale Capital sold 288 Adicet Bio shares in Q4 2022, an estimated $65K.
  • Annandale Capital first reported a position in Adicet Bio in Q3 2022 and held it in 1 quarter.
  • Annandale Capital's Adicet Bio position peaked at $65K in Q3 2022.
  • 100 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on Annandale Capital's 13F filing for Q4 2022, filed 15 Feb 2023.